exo-THC (CRM) (Synonyms: (–)-Δ7-Tetrahydrocannabinol, Δ9,11-Tetrahydrocannabinol, Δ11-Tetrahydrocannabinol, (–)-trans-Δ9,11-Tetrahydrocannabinol, exo-Tetrahydrocannabinol, (–)-Δ7-THC, (–)-trans-Δ9,11-THC) |
| Catalog No.GC52028 |
A Certified Reference Material
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 27179-28-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
exo-THC (CRM) is a certified reference material that is structurally similar to known phytocannabinoids.1,2 exo-THC is a potential impurity in the synthesis of δ9-THC .3 It is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.
1.Harvey, D.J., Gill, E.E., Slater, M., et al.Identification of the in vivo liver metabolites of (-)-D7-tetrahydrocannabinol produced by the mouseDrug Metab. Dispos.8(6)439-445(1980) 2.Compton, D.R., Rice, K.C., De Costa, B.R., et al.Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activitiesJ. Pharmacol. Exp. Ther.265(1)218-226(1993) 3.Razdan, R.K., Puttick, A.J., Zitko, B.A., et al.Hashish VI1: Conversion of (-)-δ1(6)-tetrahydrocannabinol to (-)-δ1(7)-tetrahydrocannabinol. Stability of (-)-δ1- and (-)δ1(6)-tetrahydrocannabinolsExperientia28(2_121-122(1972)
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *